PTEN Loss Is Associated with Adverse Outcomes in the Setting of Salvage Radiation Therapy
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Loss of PTEN protein is linked to worse outcomes in prostate cancer patients receiving salvage radiation therapy (SRT). This finding highlights PTEN as a key biomarker for predicting treatment success after SRT.
Area Of Science
- Oncology
- Genitourinary Oncology
- Prostate Cancer Research
Background
- Salvage radiation therapy (SRT) is a standard treatment for prostate cancer recurrence post-prostatectomy.
- Genomic biomarkers for predicting SRT outcomes are under-investigated.
Purpose Of The Study
- To evaluate the prognostic significance of molecular phenotypes (PTEN loss, ERG expression, TP53 mutation) in patients undergoing SRT.
- To identify potential biomarkers for stratifying patients and guiding treatment decisions.
Main Methods
- Retrospective analysis of 320 patients treated with SRT.
- Tissue microarrays and immunohistochemistry used to assess PTEN loss, ERG expression, and p53 overexpression.
- Cox-proportional hazard models used to analyze biochemical recurrence-free survival (bRFS) and metastasis-free survival (MFS).
Main Results
- PTEN loss was observed in 43% of patients and was associated with significantly worse bRFS and MFS.
- Homogeneous PTEN loss showed the highest risk for MFS.
- p53 overexpression (7%) also predicted worse bRFS and MFS.
- ERG expression (39%) was linked to worse MFS.
- Homogeneous PTEN loss remained an independent predictor of adverse outcomes on multivariable analysis.
Conclusions
- Loss of PTEN, assessed by immunohistochemistry, is an independent adverse prognostic factor for patients undergoing SRT for prostate cancer.
- These findings suggest PTEN status can help predict treatment response and guide future therapeutic strategies.
- Further research is needed to determine optimal treatments for patients with adverse molecular features.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...